Subsequent analyses demonstrated that first-line treatment with nivolumab plus ipilimumab resulted in a longer duration of OS than chemotherapy in patients with NSCLC, regardless of PD-L1 expression levels [76]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.